Answers are grounded in this paper and cite their sources.
Retrospective trial evaluates efficacy of split-course chemoradiotherapy in patients with distant oesophageal cancer, suggesting it may be a standard treatment option.
Objectives: To evaluate the efficacy and safety of split-course chemoradiotherapy with S-1, a novel oral fluorouracil, together with cisplatin in patients with distant oesophageal cancer stage IVb metastasis. Methods: Forty-one patients with distant oesophageal cancer metastasis and performance status 0 or 1 received split-course chemoradiotherapy with S-1 and cisplatin. All 41 patients were reviewed retrospectively. Chemoradiotherapy comprised two courses of 30-Gy radiotherapy over three weeks plus daily oral S-1 (70mg/m 2 /day) for two weeks and a 24 h cisplatin infusion (70mg/m 2 ) on Day 8, with a two week interval between the two courses. Results: The most frequent adverse events (AEs) were grade 3 and 4 neutropenia (29.2%), thrombocytopenia (9.8%), and anaemia (7.3%). Non-haematological AEs were generally mild. AEs in the initial course of chemoradiotherapy remitted during the second interval week. Overall, the complete response rate was 22.0% and endoscopic complete response rate for primary lesion was 65.9%. Thirty-one patients (75.6%) became asymptomatic and regained normal swallowing function. The overall median survival time was 12 months. Conclusion: This retrospective investigation showed that split-course chemoradiotherapy with S-1 and cisplatin had an encouraging safety profile together with good efficacy. Potentially, this regimen may become a standard for distant metastasis of oesophageal cancer stage IVb.
No takes yet. Share an insight, caveat, or question.
Iwase et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: